Anticancer agent 201
Anticancer agent 201 (Compound 2f) has IC50 values in the low micromolar range for multiple tumor cell lines. Anticancer agent 201 is highly cytotoxic to CCRF-CEM cells in vitro, inducing apotosis by activating caspase-3 in the intrinsic mitochondrial pathway and lysis of PARP, as well as reducing the expression of Bcl-2 and Bcl-XL proteins. Anticancer agent 201 can be used in cancer research.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 分子式: C34H49F3O4
- 分子量:578.75
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
Caspase アイソフォーム固有の製品をすべて表示
More
生物活性
|
Caspase-3 |
Bcl-2 |
Bcl-xL |
Anticancer agent 201 (Compound 2f) (3.5 μM, 17.5 μM; 24h) significantly induces cytotoxic reactions, increases the number of apoptotic cells, and leads to a dose-dependent reduction of mitochondrial membrane potential in CCRF-CEM cells[1].
Anticancer agent 201 (3.5 μM, 17.5 μM; 24h) blocks or slows down the G0/G1 phase cell cycle in CCRF-CEM cells, reduces the proportion of S-phase cells, and inhibits RNA synthesis[1].
Cytotoxic activities of Anticancer agent 201 against eight tumor (including multidrug resistant variants) and two normal fibroblast cell lines[1]
| Cell lines | CCRF-CEM | CEM-DNR | K562 | K562-TAX | A549 | HCT116 | HCT116p53-/- | U20S | BJ | MRC-5 |
| IC50 (μM) | 3.5 | 4.9 | 23 | 17 | 11 | 10 | 18 | 19 | ＞50 | 27 |
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:CCRF-CEM cancer cell line
-
Concentration:3.5 μM, 17.5 μM
-
Incubation Time:24h
-
Result:Induced the strongest cytotoxic reaction and the number of apoptotic cells increased significantly.
Resulted in a significant decrease in mitochondrial membrane potential of CCRF-CEM cells in a dose-dependent manner.
-
Cell Line:CCRF-CEM cancer cell line
-
Concentration:3.5 μM, 17.5 μM
-
Incubation Time:24h
-
Result:Caused the cell cycle to be blocked or slowed down in the G0/G1 phase, while the proportion of S phase cells decreases.
At 17.5 μM, the mitosis rate of the cells decreased.
At 3.5 μM increased the proportion of BRDU-positive cells.
At 17.5μM, the proportion of BRDU-positive cells decreased.
At 17.5μM, RNA synthesis almost completely stopped.
-
Cell Line:CCRF-CEM cancer cell line
-
Concentration:3.5 μM, 17.5 μM
-
Incubation Time:24h
-
Result:Leaded to decreased expression of both Bcl-2 and Bcl-XL.
At 17.5μM, caused the activation of caspase-3 and the cleavage of PARP.
化学情報
-
分子量 578.75
-
分子式 C34H49F3O4
-
SMILES
O=C1C=C(C2C[C@]3([C@@](C(C)(C2O1)C)([H])CC[C@@]4([C@]3([H])CC[C@]5([H])[C@@]6([H])[C@@H](CC[C@@]6(CC[C@]54C)C(O)=O)C(C)C)C)C)C(F)(F)F
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Anticancer agent 201 関連分類
HY-163435 関連分類
Powered by Bioz